Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET dornase alfa in aneurysmal subarachnoid haemorrhage
2023-509627-40-01Phase 3Authorised
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in subarachnoid hemorrhage (SAH) comparing Dornase alfa plus standard of care with Standard of care alone (2 arms). Primary endpoint: Excellent functional prognosis at 6 months. Planned start Oct 2024; status: authorised.
02
Drugs
dornase alfa
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2023-509627-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509627-40-01.